| Literature DB >> 27014233 |
Xiaotian Dai1, Dongsheng Zhou2, Wei Xiong1, Jiao Feng2, Wenbo Luo3, Guangming Luo1, Haijing Wang1, Fengjun Sun4, Xiangdong Zhou1.
Abstract
Pseudomonas aeruginosa strain 10265 was recovered from a patient with pneumonia in a Chinese public hospital, and it displays the carbapenem resistance phenotype due to the acquisition of a non-conjugative but mobilizable IncP-6-type plasmid p10265-KPC. p10265-KPC carries a Tn5563-borne defective mer locus, and a novel ΔISEc33-associated bla KPC-2 gene cluster without paired inverted repeats and paired direct repeats at both ends. Mobilization of this ΔISEc33-associated element in p10265-KPC would be attributed to homologous recombination-based insertion of a foreign structure Tn3-ISApu1-orf7-ISApu2- ISKpn27-Δbla TEM-1 -bla KPC-2 -ΔISKpn6- korC-orf6-klcA-ΔrepB into a pre-existent intact ISEc33, making ISEc33 truncated at the 3' end. The previously reported pCOL-1 represents the first sequenced KPC-producing IncP-6 plasmid, while p10265-KPC is the second one. These two plasmids carry two distinct bla KPC-2 gene clusters, which are inserted into the different sites of the IncP-6 backbone and have different evolutionary histories of assembly and mobilization. This is the first report of identification of the IncP-6-type resistance plasmid in China.Entities:
Keywords: IncP-6; KPC-2; Pseudomonas aeruginosa; p10265-KPC
Year: 2016 PMID: 27014233 PMCID: PMC4785139 DOI: 10.3389/fmicb.2016.00310
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Antimicrobial resistance phenotypes of Pseudomonas aeruginosa and Escherichia coli with plasmid p10265-KPC.
| Antibiotics | MIC (mg/L)/antimicrobial susceptibility | ||
|---|---|---|---|
| Ampicillin | ≥32/R | ≥32/R | 4/S |
| Ampicillin/sulbactam | ≥32/R | ≥32/R | 4/S |
| Piperacillin | ≥128/R | ≥128/R | ≤4/S |
| Piperacillin/tazobactam | ≥128/R | ≥128/R | ≤4/S |
| Cefazolin | ≥64/R | ≥64/R | ≤4/S |
| Cefuroxime sodium | ≥64/R | ≥64/R | 4/S |
| Cefuroxime axetil | ≥64/R | ≥64/R | 4/S |
| Cefotetan | ≥64/R | 32/R | ≤4/S |
| Ceftriaxone | ≥64/R | ≥64/R | ≤1/S |
| Ceftazidime | ≥64/R | ≥64/R | ≤1/S |
| Imipenem | ≥16/R | ≥16/R | ≤1/S |
| Meropenem | ≥16/R | 8/R | ≤0.25/S |
| Aztreonam | ≥64/R | ≥64/R | ≤1/S |
| Ciprofloxacin | ≥4/R | ≤0.25/S | ≤0.25/S |
| Levofloxacin | ≥8/R | ≤0.25/S | ≤0.25/S |
| Trimethoprim/sulfamethoxazole | ≥320/R | ≤20/S | ≤20/S |
| Amikacin | ≤2/S | ≤2/S | ≤2/S |
| Gentamicin | ≤1/S | ≤1/S | ≤1/S |
| Tobramycin | 2/S | ≤1/S | ≤1/S |